XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) |  | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Aug. 29, 2017 USD ($) | Sep. 30, 2017 USD ($) | Sep. 30, 2016 USD ($) | Sep. 30, 2017 USD ($) Segment | Sep. 30, 2016 USD ($) | Dec. 31, 2016 USD ($)
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Restricted cash balances as collateral for corporate credit cards |  | $ 80,000 |  | $ 80,000 |  | $ 80,000
Marketable securities, weighted average remaining maturity |  |  |  | 8 months |  |
Research and development expense |  | 8,956,468 | $ 5,852,121 | $ 23,714,932 | $ 13,941,283 |
Deferred revenue |  | 41,175,600 |  | 41,175,600 |  |
Impairment of Long-Lived Assets |  |  |  | 0 | 0 |
Impairment of goodwill |  |  |  | 0 | 0 |
Revenues from product sales to date |  |  |  | $ 0 |  |
Number of operating segments | Segment |  |  |  | 1 |  |
In-Process Research and Development |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Asset impairment charges |  | 0 | 0 | $ 0 | 0 |
Janssen and JJDC | Co-Development and License Agreement |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Research and development expense |  | 4,500,000 | $ 3,500,000 | 11,200,000 | $ 3,500,000 |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Upfront payment | $ 30,000,000 |  |  |  |  |
Accrued collaborative expenses | 11,200,000 |  |  |  |  |
Deferred revenue |  | 41,200,000 |  | 41,200,000 |  |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Upfront Payment |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Deferred revenue |  | 30,000,000 |  | 30,000,000 |  |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Previously Accrued Collaborative Expenses |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Deferred revenue |  | 11,200,000 |  | 11,200,000 |  |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Payment start of Phase | 20,000,000 |  |  |  |  |
Payment upon enrollment of patients | $ 20,000,000 |  |  |  |  |
Percentage of patients to be enrolled | 50.00% |  |  |  |  |
Accrued collaborative expenses | $ 11,200,000 |  |  |  |  |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail | Upfront Payment |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Deferred revenue |  | 30,000,000 |  | 30,000,000 |  |
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail | Previously Accrued Collaborative Expenses |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |
Deferred revenue |  | $ 11,200,000 |  | $ 11,200,000 |  |

X
- Definition Accrued research and development costs current. + References No definition available. + Details
Name: | nerv_AccruedResearchAndDevelopmentCostsCurrent
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Marketable securities, weighted average remaining maturity. + References No definition available. + Details
Name: | nerv_MarketableSecuritiesWeightedAverageRemainingMaturity
Namespace Prefix: | nerv_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of patients to be enrolled. + References No definition available. + Details
Name: | nerv_PercentageOfPatientsToBeEnrolled
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product develpoment cost payable. + References No definition available. + Details
Name: | nerv_ProductDevelpomentCostPayable
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product develpoment cost payable upon enrollment of patients. + References No definition available. + Details
Name: | nerv_ProductDevelpomentCostPayableUponEnrollmentOfPatients
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Significant accounting policies. + References No definition available. + Details
Name: | nerv_SignificantAccountingPoliciesLineItems
Namespace Prefix: | nerv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment paid. + References No definition available. + Details
Name: | nerv_UpfrontPaymentPaid
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 225 -Section 45 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84241808&loc=d3e92212-112881 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2921-110230 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsHeldForUse
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=nerv_JanssenPharmaceuticaNVAndJanssenResearchAndDevelopmentLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=nerv_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nerv_AmendmentToCoDevelopmentAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nerv_PreviouslyAccruedCollaborativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseThreeClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |